Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Aclaris Therapeutics, Inc. (ACRS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/22/2023 4 Monahan Joseph (Chief Scientific Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Sold 6,000 shares @ $7.3158, valued at $43.9k
08/21/2023 144 Form 144 - Report of proposed sale of securities:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
08/03/2023 4 Manion Douglas J. (Pres and CEO) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Paid exercise price by delivering 4,437 shares @ $9.81, valued at $43.5k
Exercised 15,575 restricted stock units @ $0
07/05/2023 4 Cawkwell Gail (Chief Medical Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Paid exercise price by delivering 5,407 shares @ $10.37, valued at $56.1k
Exercised 15,000 restricted stock units @ $0
06/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "COBRA”), Employer will continue to pay, directly to the healthcare provider when due, Employer’s portion of the medical, vision and dental coverage premiums for a period of twelve months after the effective date of Executive’s termination ; provided that, if at any time Employer determines, in its sole discretion, that the payment of the COBRA 6"
06/05/2023 4 Humphries William D. (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Granted 15,750 options to buy @ $8.7, valued at $137k
Granted 4,660 restricted stock units @ $0
Exercised 4,507 restricted stock units @ $0
06/05/2023 4 MILANO VINCENT (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Granted 15,750 options to buy @ $8.7, valued at $137k
Granted 4,660 restricted stock units @ $0
Exercised 4,507 restricted stock units @ $0
06/05/2023 4 GOWEN MAXINE (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Granted 15,750 options to buy @ $8.7, valued at $137k
Granted 4,660 restricted stock units @ $0
Exercised 4,507 restricted stock units @ $0
06/05/2023 4 Molineaux Christopher P. (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Granted 15,750 options to buy @ $8.7, valued at $137k
Granted 4,660 restricted stock units @ $0
Exercised 4,507 restricted stock units @ $0
06/05/2023 4 Reasons Bryan M. (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Granted 15,750 options to buy @ $8.7, valued at $137k
Granted 4,660 restricted stock units @ $0
Exercised 4,507 restricted stock units @ $0
06/05/2023 4 SCHIFF ANDREW N (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Granted 15,750 options to buy @ $8.7, valued at $137k
Granted 4,660 restricted stock units @ $0
Exercised 4,507 restricted stock units @ $0
06/05/2023 4 Powell Andrew Kenneth William (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Granted 15,750 options to buy @ $8.7, valued at $137k
Granted 4,660 restricted stock units @ $0
Exercised 4,507 restricted stock units @ $0
06/05/2023 4 Mehra Anand (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Granted 15,750 options to buy @ $8.7, valued at $137k
Granted 4,660 restricted stock units @ $0
Exercised 4,507 restricted stock units @ $0
06/01/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
05/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
04/20/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 ARS Form ARS - Annual Report to Security Holders:
04/14/2023 8-K Quarterly results
03/31/2023 8-K Regulation FD Disclosure  Interactive Data
03/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1 to Consulting Services Agreement, by and between the Company and Frank Ruffo"
03/17/2023 4 Manion Douglas J. (Pres and CEO) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Bought 6,300 shares @ $7.8623, valued at $49.5k
03/16/2023 SC 13G BIOTECHNOLOGY VALUE FUND L P reports a 5% stake in Aclaris Therapeutics, Inc.
03/09/2023 4 Manion Douglas J. (Pres and CEO) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Bought 6,500 shares @ $7.735, valued at $50.3k
03/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
03/03/2023 4 Walker Neal (Director) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Sold 29,000 shares @ $12.3651, valued at $358.6k
Sold 30,240 shares @ $12.6346, valued at $382.1k
Exercised 96,150 restricted stock units @ $0
Exercised 18,275 restricted stock units @ $0
Exercised 24,000 restricted stock units @ $0
Exercised 18,254 restricted stock units @ $0
03/03/2023 4 Monahan Joseph (Chief Scientific Officer) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Sold 14,800 shares @ $12.3665, valued at $183k
Sold 16,037 shares @ $12.6342, valued at $202.6k
Exercised 13,750 restricted stock units @ $0
Exercised 50,000 restricted stock units @ $0
Exercised 10,925 restricted stock units @ $0
Exercised 12,500 restricted stock units @ $0
03/03/2023 4 Balthaser Kevin (CFO) has filed a Form 4 on Aclaris Therapeutics, Inc.
Txns: Sold 1,000 shares @ $12.289, valued at $12.3k
Sold 894 shares @ $12.6281, valued at $11.3k
Exercised 1,475 restricted stock units @ $0
Exercised 1,100 restricted stock units @ $0
Exercised 2,375 restricted stock units @ $0
Exercised 1,500 restricted stock units @ $0
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy